(Read full article on inform.kz)

The 3rd phase of clinical trials of the Kazakhstani vaccine against the QazVac coronavirus has been completed. This was announced at a briefing by the Central Communications Service by the Director General of the Scientific Research Institute of Biological Safety Problems Kunsulu Zakarya, Kazinform correspondent reports.

“Indeed, all clinical trials have been completed in the third phase. On July 9, the last analyzes were collected. By the end of July, we carried out processing and statistical analysis of a huge layer of data. Three thousand people took part, the parameters were quite large. The final report at the end of July was prepared for the third phase and for the entire clinical trial. The report was submitted to the National Center for Expertise of Medicines and Medical Devices. He is currently under examination there, but we have not yet received a conclusion. But, following our report, since the report was prepared by our Institute, clinical trials of the first Kazakhstani vaccine QazVa were successful, and if our report was approved by the NCELS, we began preparing an article for the next leading top-rated journal in order to show the success of Kazakhstani science,” said Kunsulu Zakarya.